Project Description Discovery
Psoriasis A new topical formulation for psoriasis.
Launched in several markets including the US and Europe.
Topical formulation A topical formulation for scalp and body psoriasis.
LP0053 Development ongoing to bring the treatment to Japan.
Topical formulation
LP0076 An IL-17 receptor monoclonal antibody under regulatory
Brodalumab review for people with psoriasis.
LP0160 A systemic anti-in ammatory compound intended to o er an oral
Oral PDE4i long-term treatment option for people with moderate to severe psoriasis.
LP0058 A new xed-dose combination for topical use
Fast drying spray with fast drying and low greasiness.
LP0113 An electronic equipment intended to help people with
SmartTop™ skin conditions to adhere with a topical treatment.
LP0123
Eczema An IL-13 anti-in ammatory monoclonal antibody under
development for people with atopic dermatitis.
Tralokinumab
LP0162 A topical treatment for in ammatory skin diseases using a pan-JAK inhibitor, intended
JAK Topical to o er an improved safety pro le compared to topical steroids.
LP0133
Topical PDE4i An anti-in ammatory non-steroidal topical treatment for people with atopic dermatitis intended
LP0108 to o er an improved safety pro le compared to topical steroids.
SEGRA
LP0155 A selective glucocorticoid non-steroidal receptor agonist for topical treatment of atopic dermatitis,
ARGX-112 intended to o er an improved safety pro le compared to topical steroids.
LP0145
An anti-in ammatory monoclonal antibody
for the treatment of atopic dermatitis.
Skin cancers
Ingenol disoxate A novel topical compound for the treatment
LP0084 of actinic keratosis in large areas.
PoC Filed/
regulatory
y Ph1 Ph2a Ph 2b Ph3 approval Launch